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Abstract
Rapid advances in high–throughput technologies have led to considerable interest in analyzing genome–
scale data in the context of biological pathways, with the goal of identifying functional systems that are
involved in a given phenotype. In the most common approaches, biological pathways are modeled as
simple sets of genes, neglecting the network of interactions comprising the pathway and treating all
genes as equally important to the pathway’s function. Recently, a number of new methods have been
proposed to integrate pathway topology in the analyses, harnessing existing knowledge and enabling more
nuanced models of complex biological systems. However, there is little guidance available to researches
choosing between these methods. In this review, we discuss eight topology-based methods, comparing
their methodological approaches and appropriate use cases. In addition, we present the results of the
application of these methods to a curated set of ten gene expression profiling studies using a common set
of pathway annotations. We report the computational efficiency of the methods and the consistency of
the results across methods and studies to help guide users in choosing a method. We also discuss the
challenges and future outlook for improved network analysis methodologies.
Introduction
Modern high–throughput (HT) technologies enable researchers to make comprehensive measurements of the
molecular state of biological samples and have yielded a wealth of information regarding the association
of genes with specific phenotypes. However, the complex and adaptive nature of living systems presents
a significant challenge to deriving accurate and predictive mechanistic models from genomic data. Because
cellular processes are governed by networks of molecular interactions, critical alterations to these systems may
arise at different points yet result in similar phenotypes. At the same time, the adaptability and robustness
of living systems enables variations to be tolerated. Typical gene–level analyses of HT data, such as tests
of differential expression, are unable capture these effects. As a result, there has been growing interest in
systems–level analyses of genomic data.
Pathway analysis techniques, which aim to examine HT data in the context of mechanistically related
gene sets, have been enabled by the growth of databases describing functional networks of interactions.
These include KEGG [1], BioCarta [2], Reactome [3], the NCI Pathway Interaction Database (NCI-PID) [4],
and InnateDB [5], amongst others. To address the challenge of querying these databases using a common
framework, markup languages such as KGML (used by KEGG) and BioPAX have been developed to describe
pathways using a consistent format. In particular, the Biological Pathway Exchange (BioPAX) project now
provides a unified view of the data from many of the above sources [6], including NCI-PID, Reactome,
BioCarta, and WikiPathways.
Over the past decade, a number of pathway analysis methods have been developed to integrate this
information with data derived from genomic studies [7]. These methods can be broadly grouped into two
categories. The first category comprises analyses designed to identify pathways in which significant genes are
overrepresented. A comprehensive review of these methods was recently published Khatri &al [7]; examples
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include hypergeometric tests, Gene Set Enrichment Analysis (GSEA) [8], and Ingenuity Pathway Analysis [9].
The second category of approaches use dimension reduction algorithms to summarize the variation of the
genes across the pathway and test for pathway–level differences without relying on single–gene association
statistics. Examples include GPC-Score [10], Pathifier [11], and PDM [12]. In contrast to enrichment
analyses like GSEA, these methods are capable of identifying differences at the systems–level that would
be indetectable by methods that rely upon single–gene association statistics, such as differences in the
coordination of the expression of two genes.
Despite these advances, the majority of these methods treat pathways as simple lists of genes, neglecting
the network of interactions codified in pathway databases (cf. Fig 1) despite the fact that the importance of
pathway network structure to biological function has long been appreciated. In [13], the authors presented
systematic mathematical analysis of the topology of metabolic networks of 43 organisms representing all
three domains of life, and found that despite significant variation in the pathway components, these networks
share common mathematical properties which enhance error-tolerance. In [14], the authors compared the
lethality of mutations in yeast with the positions of the affected protein in known pathways, and found that
the biological necessity of the protein was well modeled by its connectivity in the network.
To incorporate known interaction network topology with traditional pathway analyses, a multitude of
approaches have been proposed for overlaying gene–specific data (either the raw data itself or p-values
derived from gene–level statistical tests) onto pathway networks [15–34]. However, to date few comparisons
between them have been made. One recent review [35] attempted to compare three network–based analyses
(SPIA, PARADIGM, and PathOlogist); unfortunately, the comparison was stymied by the methods’ disparate
implementations and reference databases, and yielded inconclusive results. To address this gap, we review
eight topology–based pathway analysis methods [8, 15–26, 36]. While this is not a comprehensive review
of all such algorithms, the methods we consider have the common feature of being implemented in R and
permitting the user to provide the pathway models (such as those obtained from KEGG), thus allowing
them to be compared directly without the issues encountered in [35]. Their free availability from CRAN and
BioConductor [37] also makes them the most popular network analysis methods in the bioinformatics and
computational biology research community.
Below, we briefly describe each method and discuss its features and limitations. In addition, we also
provide a comparison of these methods applied to a curated set of gene expression data from 10 ovarian
cancer studies [38], using a common set of 247 KEGG pathways. Using this data, we were able to evaluate
both the computational efficiency of the methods and the consistency of the results between the methods
and across the studies. The suite of data and scripts used in this comparison are available from our website,
enabling researchers to compare updated versions and new network analysis packages using this common
framework.
Overview of Network Pathway Analysis Methods
We consider 8 popular network-based pathway analysis methods, described below. In the following discussion,
we consider a pathway to be a network of genes (nodes), where edges represent a biochemical interaction.
These edges may be directed (e.g., gene i induces gene j, but not vice-versa) or signed (e.g., +1 for acti-
vation or induction, −1 for repression or inhibition). Also, while the following methods were designed with
differential expression analyses in mind, it should be noted that most are flexible enough to accommodate
other statistics or data types (e.g., allele frequencies and χ2 statistics from GWAS). A summary of the key
features of the methods is given in Table 1. For comparison, we also consider GSEA [8], a commonly–used
pathway analysis algorithm that does not incorporate network topology.
GSEA Gene Set Enrichment Analysis (GSEA) [8] is an extremely popular method for detecting pathways
that are enriched for differentially expressed genes. In contrast to simple hypergeometric overrepresentation
analysis, GSEA does not require a threshold for calling a gene significant, but rather considers the magnitude
of the expression changes for all the genes in the pathway. Briefly, the algorithm ranks all assayed genes
according to the significance of the gene–level associations, and computes a running sum statistic to test
whether the genes on the pathway of interest tend to lie at the top of the ranked list (vs. a null hypothesis
of being randomly distributed). Significant pathways are those whose genes occur higher in the ranked list
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than expected by chance, resulting in a sharply peaked running sum statistic. The size of this peak, called
the enrichment score (ES), is tested for significance by permuting the sample labels and recalculating the
test statistic to generate a null distribution. This procedure identifies pathways with an accumulation of
differentially expressed genes that are associated with the phenotypes of interest. As its name suggests,
however, GSEA treats pathways as sets of genes, without incorporating network topology.
SPIA Signaling Pathway Impact Analysis (SPIA) [15], and the related ROntoTools/Pathway-Express
method described below, are methods designed to quantify the impact that differentially expressed (DE)
genes have on the downstream elements of the pathway by taking into account the number of DE genes,
the magnitude of the expression differences, and the direction and type of edges in the pathway. In SPIA, a
“perturbation factor” is computed for each gene g, defined as the weighted sum of the expression differences
of all the DE genes which are direct upstream parents of g in the network. The weighting coefficients are a
function of both the number of outgoing edges of the parent node, as well as the type of edge (positive for
induction/activation, negative for repression/inhibition) connecting the parent to the child node g. The total
accumulated perturbations of all genes in the pathway is compared against a null distribution obtained by
repeatedly randomizing the observed expression differences to different genes in the network. SPIA combines
the resulting perturbation p value, p.PERT, with the p value from the simple hypergeometric overrepresenta-
tion test for the pathway, p.ORA, using Stouffer’s weighted-z method [39], yielding a pathway graph p value
(p.Comb). Thus, a pathway with DE genes at its entry point could be deemed more significant than one
with DE genes further downstream, even if the fold changes are smaller.
Although SPIA is described in the context of differential gene expression, the method can in principle be
used with any type of gene-level association statistic (e.g., hazard ratios for survival, minor allele frequencies
of SNP variants, or multivariate F or T 2 statistics testing association across more than two phenotypes).
However, SPIA requires that the user set a significance threshold to select the genes that are considered in
the analysis.
ROntoTools/Pathway Express ROntoTools/Pathway Express (ROT/pe) [16–18] is a refinement upon
SPIA. In SPIA, a gene significance threshold is used to select DE genes, and the DE genes are treated equally,
while those that are not DE are not considered in the analysis. To enable a more nuanced analysis, ROT/pe
weights the change in expression of each gene by the significance of the gene level statistics. As a result,
marginally significant changes in expression are given less weight than a highly significant changes of the same
magnitude. Furthermore, this method permits a “cut-off free” analysis that assigns non-significant genes a
low weight rather than aggressively discarding them as non-DE. When no cutoff is used, ROT/pe does not
calculate the overrepresentation significance p.ORA, but simply reports the significance of the perturbation
(obtained, as in SPIA, by randomly permuting the gene expression differences across the network).
PathNet PathNet [19] incorporates pathway topology by computing both a “direct” and “indirect” associa-
tion statistic for each gene. The “direct” statistic is the result of a single–gene association test (e.g., a classical
t test of differential expression). Once these are obtained, PathNet then computes “indirect” statistic for each
gene, defined as the sum of the − log10 p values of the direct associations for all the gene’s neighbors in the
pathway. The direct and indirect scores for each gene are summed and tested for significance by permuting
the direct evidence statistic across all genes in a “global” network formed by merging pathways with common
genes. The resulting gene–level p values are then thresholded for significance, and the pathway is tested for
enrichment using a hypergeometric test.
Like SPIA and ROT/pe, PathNet can accommodate a variety of gene–level metrics and is not restricted to
simple differential expression. In contrast to SPIA and ROT/pe, PathNet considers all possible edges in the
global network, not simply those confined to a single pathway, enabling it to find pathways that are strongly
affected through indirect links. Also in contrast to both SPIA and ROT/pe, PathNet does not distinguish
between inhibitory and activating edges. PathNet’s use of thresholding for testing pathway significance is
also a drawback, but could easily be overcome by using a GSEA-like procedure instead of the hypergeometric
test.
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NEA As in PathNet, Network Enrichment Analysis (NEA) [20,21] also attempts to incorporate information
from the “global” network of pathways formed by merging the common genes in the individual functional
pathways represented in the database, but uses a different approach to quantify enrichment. Rather than
counting significant nodes (i.e. genes) in each pathway of interest, NEA counts the number of edges in the
pathway connecting to a significance gene. This is done by summing the degree (i.e., number of edges)
for each DE gene on the pathway and amongst its neighbors, subtracting out links from genes that do not
connect to a gene in the pathway. Genes outside the pathway will thus contribute to the pathway’s score;
connections between two DE genes on the pathway are counted twice (once per each gene). NEA assess
the significance of this statistic by randomly rewiring the topology of the “global” network, conditioned on
preserving the degree of each node.
Like all the foregoing methods, any gene-level statistic of interest may be used as an input to NEA.
However, NEA as implemented is dependent upon setting cutoffs for gene significance in order to count the
number of DE links, making the results susceptible to noise induced by thresholding. It may be of interest
to investigate possible refinements of NEA using a weighting scheme rather than a strict binary cutoff. Also,
NEA as currently implemented does not consider the direction of the edges in the graph, but rather treats
all edges as bi-directional. Direction-based refinements to NEA may thus also be of interest.
CePa All of the above methods improve upon GSEA by not only considering each gene’s differential
expression, but also examining the differential expression of its nearest–neighbors (“perturbations” from
upstream genes in SPIA and ROT/pe, “indirect evidence” in PathNet, number of DE links in NEA). The
resulting pathway scores thus represent an accumulation of localized effects within the pathway. In contrast
to these approaches, CePa [22, 23] attempts to take a broader view of the network by incorporating graph
centrality measures into the statistics.
Briefly, the “centrality” of a node in a graph is a measurement of its relative importance to the rest of the
network [40]. One simple centrality measure is the node’s degree: the number of edges connecting to that
node. On a directed graph, the in–/out–degrees, which are the counts of a node’s incoming/outgoing edges
respectively, are also useful for quantifying how susceptible/influential a node is. “Betweenness,” another
centrality measure, quantifies how frequently the shortest path between any two nodes goes through the
node of interest.
CePa uses the centrality measures of the genes in the network to perform either an “over representation
analysis” (CePa-ORA) or a “gene set analysis” (CePa-GSA). In CePa-ORA, the user specifies a set of sig-
nificant genes (based on some pre-determined significance threshold); CePa-ORA then sums the centrality
measures of the significant genes and calculates the significance of the sum by randomly selecting a new set
of “significant” genes based on the proportion of truly observed significant genes in the network. That is,
CePa-ORA tests whether significant differential expression is more likely to be high–centrality nodes in the
pathway than would be expected by chance.
The CePa–GSA variant incorporates the gene–level statistics (such as the t statistic from a test of differ-
ential expression) rather than using only the list of significant genes. CePa-GSA multiplies the gene statistics
by the gene centrality measures. In this way, CePa directly weights each gene’s statistic by its importance in
the network, reflecting the observation made by Jeong and others [14] that alterations to more central genes
have a more profound impact on an organism. CePa–GSA then aggregates the weighted gene–level statistics
into a single pathway–level statistic by taking, for example, their maximum or median. As implemented in
the CePa package, the default gene–level statistic is the absolute value of the t statistic from a two–sample
test of differential expression, and the default pathway–level statistic is the mean of the centrality–weighted
gene–level statistics. The significance of this pathway–level score is calculated by permuting the sample labels
of the the gene expression matrix, recomputing the gene–level statistics with the permuted samples, and then
recomputing the pathway statistic. The resulting p value quantifies the differences in centrality–weighted
gene expression that are associated with the phenotypic differences of interest.
While in principle both CePa-ORA and CePa-GSA can use any gene–level statistics, at present the
implementation of CePa-GSA is such that the user is confined only to two–sample t–tests of differential
expression. If, for instance, the outcome of interest is survival (yielding hazard ratios for each gene), or if
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differences across multiple conditions or phenotypes are being assessed with a multivariate linear model or
ANOVA, or if the input data is categorical rather than continuous (such as allele frequencies from SNP GWAS
studies), the user has no choice other than to precompute the gene–level p values and use the thresholded
CePa-ORA analysis rather than the more nuanced CePa-GSA approach. It would be of considerable interest
to address this limitation by providing a more flexible interface to CePa-GSA that permits user–defined
models. In addition, while CePa provides a very rich view of the centrality–weighted pathway analysis, the
variety of statistics it obtains (one per each of 6 centrality metrics considered) and the diverse options for
pathway aggregation (max, mean, etc., as well as the option for user–defined function) can make the results
difficult to interpret. Finally, it may also be argued that linear centrality–weighting (as opposed to, e.g.,
weighing by a power function of the centrality) is an arbitrary choice that may influence the results.
DEGraph An alternative topology–weighting approach is implemented in DEGraph [24], which uses a
multivariate Hotelling T 2 test to identify pathways in which a significant subset of genes are differentially
expressed. In DEGraph, both the standard T 2 and a network–smoothed graph T 2 are computed. Based
on the intuition that two genes connected in the network should behave in a correlated fashion, DEGraph’s
network–smoothing filters the gene expression differences by keeping only the first few components of its
projection onto a basis defined by the graph Laplacian [41]. Spectral decomposition of the pathway’s graph
Laplacian encapsulates the geometry of the network topology at progressively finer scales, and the projection
of the gene expression shifts onto the coarsest components may be analogized to keeping only the lowest
frequency Fourier components of a function. These network–smoothed shifts are then tested using the
Hotelling T 2 test.
Unlike CePa, DEGraph provides a means to obtain pathway–wide topology–weighted scores without
making arbitrary choices about the weighting. In particular, the mathematical and statistical properties
of graph Laplacian spectra are well–characterized [41, 42] and can be precisely related to the dynamical
properties of the network [43,44], making this approach more justifiable than the weighting scheme proposed
in CePa. However, this spectral approach is necessarily confined to operate only on connected components,
posing problems for pathways comprising several disjoint subgraphs (e.g., two sub-processes connected by a
exogenous stimulus that is not represented in the gene network). In such cases, the pathway will have several
T 2 statistics—one for each connected component—leaving a choice as to whether the pathway p value should
be defined by that of its largest subnetwork or some combination of all its subnetworks. In addition, the
use of the Hotelling T 2 test requires that the gene–level statistics follow a multivariate normal distribution,
which limits the types of data and analyses to which DEGraph could be applied. In consequence, the
DEGraph implementation is only capable of testing pathway–wide multi–gene differential expression between
two sample classes. Recently, a more flexible spectral decomposition method has been proposed [31,45], but
which relies upon computationally intensive permutation tests. It would be highly interesting to extend
DEGraph to accommodate other data types and statistical tests.
Topology GSA Although analyzing the data at the pathway level can identify important systems–level
changes that would be missed by single–gene analyses, the pathway–level findings can be difficult to in-
terpret and validate for large networks. While identifying functionally significant pathways is the goal of
systems biology, it is often necessary to identify specific features within those networks that can be tar-
getted experimentally. To facilitate the discovery of targetable sets of genes and interactions, a number
of techniques have been proposed to search for significant submodules within pathways. One such method
is TopologyGSA [25, 26], which uses a Gaussian network model to identify significant subnetworks in the
graph. TopologyGSA begins by transforming the directed pathway network graph into its so–called “moral”
graph by connecting all “parent” nodes of a vertex and removing the edge directionality. The moral graph
is then decomposed into cliques: subsets of nodes in the graph for which every pair is connected by an edge
(triangles are the simplest cliques; a clique of four nodes has 6 edges; a clique of five has 10; etc). Each clique
is then tested for differential expression by modeling the expression of the genes in the network as Gaussian
random variables, subject to the class–conditional covariance between the clique’s genes for each phenotype.
If no significant cliques are found, edges are iteratively added and the statistics recomputed. The result is
the identification not only of pathways with significant gene expression differences, but of specific connected
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subgraphs within the pathways that can then be investigated in greater detail.
An appealing feature of TopologyGSA is the use of gene covariance in the analysis. Despite the fact
that genes often exhibit considerable correlations in expression, most pathway analyses consider the genes as
independent variables. However, TopologyGSA’s approach of conditioning the clique statistics on phenotype–
specific covariances also introduces a limitation: like DEGraph, it can only be used if the outcome of interest
can be dichotomized.
Moreover, while testing cliques of a triangulated graph to detect significant subnetworks is an interesting
idea, it has a very serious drawback: finding all maximal cliques in a graph is an NP -hard problem, meaning
that a solution is not guaranteed in polynomial time. In particular, a brute-force search for a clique of size k
in a graph with n nodes has a computational complexity of O(nkk2). While approximations can be made, a
recent proof by Chen [46] demonstrated that the clique problem cannot be solved in less than f(k)no(k) time
for any function f and linear function o(k). As the size of the pathway n grows, the size of the submodule
cliques k also increases, and time needed to search for those submodules increases exponentially. This means
that for larger pathways—often the very ones for which submodule detection is desirable—the problem
TopologyGSA attempts to solve may be intractable. Because TopologyGSA iteratively adds edges as part of
the significance computation, the exponential cost is incurred on each iteration. A far more efficient approach
would be to use spectral methods to identify communities of nodes [41, 42, 47, 48] rather than articulating
all maximal cliques. Such an approach, which would be closely related to yet still distinct from the spectral
used in DEGraph [24] and Pathway/PDM [31, 45], would permit the identification of connected subnets of
significant genes far more efficiently than solving the clique problem.
Evaluating the Performance of Network Analysis Methods
As described above and shown in Table 1, these network analysis methods have different features that
make them better suited to some use cases than others. Nevertheless, for many common analyses, most of
these approaches could be applied, and the user is faced with a choice between several promising methods.
Unfortunately, benchmark tests to systematically evaluate the performance of network analysis methods
remain lacking, limiting the community’s ability to compare methods.
The development of a systematic evaluation framework faces a number of challenges. First, the methods
themselves have highly disparate implementations, often using different databases and pathway semantics,
making them difficult to compare in a consistent way. For example, PathOlogist [32, 33] treats pathways
as bipartite graphs of genes and interactions in contrast to the gene–mode networks considered by the
methods described above, and is restricted in its implementation to pathways from the NCI/PID [4] database.
Secondly, it is not clear what the “gold standard” for these methods should be. Unlike machine learning and
network inference problems which are readily tested against simulated benchmark data with known solutions
(such as the in-silico data suites used in the DREAM Challenges [49]), there is no agreement on what the
“correct” results of these analyses would be.
To provide intuition regarding the performance of the methods reviewed here, we systematically applied
them to a curated suite of gene expression data from 10 ovarian cancer studies [38] using a common set
of pathway definitions obtained from the KEGG database. The goal of these tests was not only to supply
provisional guidance about the relative performance of the methods, but also to suggest a strategy for a
testing framework for pathway analysis methods.
Methods
Our approach is motivated by the observation that systems–level analyses improve the concordance of results
between different studies of the same phenotype [45, 50]. Although multiple studies of the same phenotype
may yield very different lists of significant genes, pathway analyses tend to to show much greater agreement.
This effect is not unexpected, considering the complexity of biological systems [51] and the noisiness of HT
data; individual disease–associated genes may be detected in some studies but miss the significance threshold
in others. However, if a pathway is functionally related to the disease, we may reasonably expect to detect
its association across multiple studies, even if the specific genes contributing to its significance vary from one
study to the next.
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This observation leads to the following conjectures: If a specific pathway is functionally related to a
particular phenotype, we expect that some manifestation of its involvement will be present in the data for
all studies of that disease, and that an accurate and sensitive network analysis approach will detect those
signals consistently across the studies. A poor network analysis method, on the other hand, will yield results
that are strongly influenced by noise in the data, and hence will detect pathways that are particular to each
study rather than the common biological signal. On the basis of this conjecture, we use the cross–study
concordance of each method’s results to measure its ability to detect a common (and presumably “true”)
signal in each of the studies.
Ovarian Cancer Data
For the purposes of our analysis, we used gene expression and clinical information from curatedOvarian-
Data [38], an expert–curated collection of uniformly prepared microarray data and documented clinical
metadata from 23 ovarian cancer studies totalling 2970 patients. The curatedOvarianData project was de-
signed to facilitate gene expression meta-analysis as well as software development. By providing a consistent
representation of data that has been processed to ensure comparability between studies, the package enables
users to immediately analyze the data without needing to reconcile different microarray technologies, study
designs, expression preprocessing methods, or clinical data formats.
Because several of the methods under consideration were limited to two–sample comparisons, we selected
data sets with sample classes that could be meaningfully dichotomized. Since the vast majority of the samples
came from patients with stage III cancers, tumor/normal and stage–based comparisons were not feasible;
instead, we chose to compare low– and high–grade ovarian serous carcinomas. These grades have distinct
histological features, molecular characteristics, and clinical outcomes [52, 53]. Low–grade serous carcinomas
typically evolve slowly from adenofibromas, acquiring over time frequent mutations to KRAS, BRAF, or
ERBB2 genes, but not TP53 mutations. In contrast, high–grade serous carcinomas are characterized by
TP53 mutations, often without mutations to KRAS, BRAF, or ERBB2. They arise from unknown precursor
lesions, progress rapidly, and have worse clinical outcomes. For this analysis, we selected studies with a
minimum of 15 high– and low–grade serous carcinomas and 1000 genes assayed, keeping only the patients
who fell into those categories and who had survival data. 10 of the 23 available studies met these criteria.
The study accession numbers and sample counts are given in Table 2.
The microarray data was filtered to keep only the genes common to all 10 studies; no other filtering was
done. This resulted in 7680 genes common to all 10 studies.
To obtain the gene–level statistics required by several of the analyses, the R limma package [54] was used.
log2 fold changes were used for the magnitude of differential expression when required; the significance of
the association was quantified using the p value for the empirical Bayes estimated t statistic [54]. Where
thresholds for significance were needed, the 0.05 most significant genes were selected. (NB, this corresponds
to the 0.05 quantile of significance, not p = 0.05. Because the studies varied considerably in their sample
sizes, and hence power, we chose to use a quantile–based threshold rather than a p value threshold to render
them comparable. While the p value for the 0.05 quantile varied from study to study, in all cases this
corresponded to p 0.05.)
Network Models
In order to ensure that each of the eight methods tested used a common, comparable set of pathway defini-
tions, we created the pathway annotation objects required for each method by hand from a fresh download of
the KEGG pathway database [1]. The KEGGgraph R package [55] was used to obtain the pathway KGML
files for 247 human pathways. The KGML files were first processed into R graphNEL objects for use by ROn-
toTools/PathwayExpress (ROT/pe), TopologyGSA,and DEGraph. The graphNEL objects were then used to
to generate the lists of genes, edges, and adjacency matrices variously required by GSEA, PathNet, NEA,
and CePa. The path.info data used by SPIA was also generated from the KEGG graphNEL objects and
written to disk as required by SPIA. In this way, we ensured that the set of pathways considered by each
method would be directly comparable to each other. The complete set of pathway annotation objects for all
the methods, along with an R script to generate a complete set of updated mappings from a fresh KEGG
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download, is available from http://braun.tx0.org/netRev.
Application
Each of the methods shown in Table 1 was applied to all 10 data sets described in Table 2 for all 247 KEGG
pathways in out database. Where permutation tests were required, 1000 permutations were used. Several of
the methods have options that permit different styles of analysis, which we also explored. The details of our
application is given below:
GSEA
As a point of reference, the non–networked GSEA was applied as described in [56], using the gene
p-values obtained from limma as described above. Significance was tested using 1000 permutations of
the sample classes.
SPIA
SPIA was applied using an 0.05–quantile threshold for significance as described above. A number of the
pathways had no edges considered by SPIA (which only considers directed edges, cf. [15, 36]), and so
were preemptively excluded from the analysis by the package. The overrepresentation and perturbation
p-values were combined using Stouffer’s normal–inverse method.
ROT/pe, cutoff
ROT/pe permits analysis with and without a p value threshold [16–18]; we applied both. Here, we
used the same threshold as in SPIA, meaning that the results should be roughly comparable to SPIA
for the p.ORA overrepresentation analysis. In contrast to SPIA, however, pPert is now weighted by the
gene’s significance, rather than treating all significant genes equally. Genes not meeting the significance
threshold are excluded from p.Pert with 0 weight, similar to the exclusion in SPIA. p.Pert and p.ORA
were combined as in SPIA.
ROT/pe, no cut
We performed ROT/pe without a significance threshold. Because the hypergeometric test cannot be
performed without setting a cut-off, only pPert is reported. In contrast to the thresholded analysis,
pPert now involves data from all the genes, although those with low significance will have low weighing.
PathNet
PathNet was carried out as described above and in [19]. PathNet returns both the PathNet p value
combining the “direct” and “indirect” evidence, along with the simple hypergeometric p value. The
quantity of interest is pPathNet.
NEA
NEA was carried out as described above and in [20,21], using the same gene thresholds and number of
permutations as in the other studies.
CePa-ORA
Like ROT/pe, CePa also has options to perform the analyses with or without setting a gene–significance
threshold [22, 23]. We performed both; here, we use the same thresholds used in the other analyses to
carry out CePa-ORA. As described above, CePa will report the significance using a variety of network
centrality measures. Because there is no clear choice of which one is correct, we chose to combine all
six measures into a single p value for CePa-ORA using Stouffer’s method.
CePa-GSA
We also performed the non-thresholded CePa-GSA. The analysis differs from CePa-ORA not only in
the number of genes considered, but also in the type of hypothesis test performed. While CePa-ORA
tests a “competitive” hypothesis [7] comparing pathways to random subsets of genes while holding
fixed the sample labels (and hence the gene–level statistics), CePa-GSA tests the “self–contained” null
hypothesis by permuting the sample labels while holding the pathway definition fixed (see Table 1).
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The two tests are orthogonal to each other, and we do not anticipate that the results of CePa-GSA
will necessarily be the same as those for CePa-ORA. As in CePa-ORA, we chose to combine the six p’s
into one p value for CePa-GSA using Stouffer’s method.
DEGraph
DEGraph also presents several alternative analysis approaches, specifically, whether or not the network
should be signed (corresponding to inversely–related nodes) or unsigned for the purposes of computing
the smoothing vector [24]. We performed both the signed and unsigned analyses. For each of these,
we also had to make a decision regarding how to handle pathways with more than one connected
component, and hence more than one p-value. We tried both simply taking the p value for the largest
connected component as the p value for the pathway, as well as combining the p values for all the
components using Stouffer’s method. DEGraph will report both the non-networked p(T 2) as well as
the graph–smoothed p(T 2)graph; the latter is the primary quantity of interest.
TopologyGSA
Finally, we attempted to apply TopologyGSA [25,26] as implemented to our data. In principle, Topol-
ogyGSA reports p values for both differential variance and differential mean expression across the
pathway submodules, both of which are of interest.
Results
Computational efficiency
The computational time to complete each each of the analyses on a desktop machine (3.4 GHz quad-core
Intel Core i7 iMac with 16GB RAM) is given in Table 3. Each of the methods shown in Table 1 was applied
to all 10 data sets described in Table 2 for 247 pathways. Where permutation tests were required, 1000
permutations were used. All jobs completed the calculation in under an hour per study with the exception
of NEA, which required ∼2.5 hrs/study, and TopologyGSA, which failed to complete even the first analysis
when it was finally halted after 100hrs (>4 days). Interestingly, ROT/pe, which is a weighted modification
of the same computation carried out in SPIA, required less time than SPIA (and, additionally, was able to
treat more pathways), which we attribute to code improvements by the authors of both methods [15–18,36]
and made ROT/pe amongst the fastest of the methods we tested. Nevertheless, with most methods taking
only a few minutes per study, the differences in computational cost between them are minor.
With the exception of TopologyGSA, which we will return to below, and DEGraph, the major computa-
tional cost is due to permutation testing. (In DEGraph, the computation of the smoothing vector scales as
O(n3) where n is the number of genes in the pathway graph, and so can be cumbersome for very large path-
ways; however, DEGraph does not require permutation tests.) Permutation testing is trivially parallelizable,
and the development of parallel R libraries such as snow [57] facilitates development of packages that can be
run on clusters. Yet, of the packages considered here, only CePa provides a parallelized implementation.
On inspection, it became clear that TopologyGSA had been working for over 90 CPU hours to obtain the
maximal cliques for a single pathway. As expected, the clique problem had become intractable; an example of
the computational cost of the clique algorithm used in TopologyGSA for a moderately sized KEGG network
is given in Supplementary Table S1. Unfortunately, TopologyGSA has no mechanism built in to monitor
and bail out of the computation, nor does it check the size of the transformed pathway before invoking the
max clique algorithm so that potentially problematic pathways can be skipped. Running TopologyGSA thus
requires that the user confine the analyses to smaller pathways, but because the computation depends on the
density of the graph after moralization and triangularization, doing so is not as simple as merely selecting
smaller pathways. While the user could transform the graphs by hand to make a selection of tractable
pathways, these checks should really be built into the package. The issue of exponential cost should also be
well–documented, ideally with a small benchmark that the user can run to estimate the computational time
required on their machine (e.g., extrapolating from a table such as Supplementary Table S1), so that the
user can make informed decisions about the application of the method to particular pathways.
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Analyses
As discussed above, we posit that if a pathway is functionally related to a particular phenotype (here, high
vs. low grade ovarian cancer), we expect that a manifestation of its involvement will be present in the
data for all studies of that disease, and that an accurate and sensitive network analysis approach will detect
those signals consistently across the studies while a poor network analysis method will yield results that are
strongly influenced by noise in the data and will vary strongly from one study to another. Based on this
intuition, we consider the cross–study concordance of each method’s results to measure its ability to detect
a common (and presumably “true”) signal in each of the studies.
Cross–study concordance For each method tested, we examined the correlation of p-values obtained for
the 247 pathways between all 45 possible pairs of the 10 studies listed in Table 2. For reference, we also
began by examining the correlation in gene–level statistics between the studies. Because each method has a
different range/resolution of possible p values owing to the different uses of parametric and nonparametric
tests, we use the nonparametric Spearman’s rank correlation as a measure of concordance.
Figure 2 depicts the correlation of results for all all 45 study pairs. For completeness, we show the cross–
study correlations for each method’s subanalyses, in addition to the “final” combined result. This includes
the pORA and pPert values for SPIA and ROT/pe (both with and without a cutoff) that are combined
to form the final pComb value for the pathway; the standard pHyper hypergeometric test along with the
network edge–based hypergeometric test from PathNet; the results for all six centrality measures considered
by CePa ORA and GSA analyses, which are then combined into pComb; and the DEGraph results for the
standard Hotelling T 2 and the network–smoothed pT2graph for the largest connected component (lcc) and
the full pathway (p’s for all connected componenents combined) for both the signed and unsigned analyses.
The “final” results for each analysis are denoted by bolding. Supplementary Figure File S1 provides a more
detailed view of the these correlations. To aid in the interpretation of Fig. 2, Fig. 3 presents a summary of
the cross–study correlations for each of the “final” results. Here, the distribution of correlations for each of
the 10 studies with respect to all other studies is shown for each of the methods.
As can be seen in the top row of Fig. 2 and first panel of Fig. 3, the correlation of gene–level statistics
is often poor; we obtained a maximum rank correlation ρ = 0.20 for the gene p-values, with a median
of ∼ 0.02. This lack of correspondence even amongst studies of the same phenotype has been observed
in other investigations of microarray data [50]. Also as previously observed in other studies [45, 50], we
found that the correlations were generally improved in pathway analyses, both in terms of the number of
positively–correlated study pairs (fewer blue cells in Fig. 2) and in the magnitude of the positive correlations
(cf Figs. 2,3). Considering that each study is interrogating gene expression in the same phenotypes, we
ideally desire that the correlations between all study pairs should be positive, and indeed many were, with
the CePa GSA analyses being the strongest and most consistent (cf Fig. 3).
In addition, we also observe that the concordance for the network–based analyses was always stronger
than that exhibited by non–network analyses. In Fig. 2, this can be seen in the darker blue cells of GSEA
and both SPIA and ROT/pe pORA sub-analysis values, all of which measure enrichment without considering
the network topology. In Fig. 3, this difference is manifest by the lower medians and tails for the GSEA
boxplot versus the others.
It is also instructive to consider the cross–study correlations for each method in the context of the gene–
level concordance and the sample size of the studies. The study pairs depicted in Fig. 2 are sorted in order
of gene–level concordance. Generally, we expect that studies which have greater similarity at the gene level
will also exhibit greater similarity in the pathway statistics, and in most cases this pattern holds, with lower
correlations at the left end of the plot. Qualitative departures from this trend can be seen in the SPIA,
NEA, and CePa–ORA betweenness results. Moreover, we expect that two large studies will exhibit greater
correlation than two smaller studies, on the basis of the intuition that two large studies are better powered
to distinguish subtle but biologically meaningful, and hence consistent, effects from noise. In Fig. 2, the sum
of the sample sizes for each study pair is given in the bottom row, and the pattern of study sizes can be seen
to be most strongly manifest in the various CePa analyses.
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Consistency between methods A similar intuition regarding the concordance of findings may be had
regarding the results of the various methods within a given study. That is, despite the differences between the
methods, we might reasonably expect that if a pathway is strongly affected in a particular study, it will be
detected by more than one of these methods, i.e., that for a given study the results from SPIA, ROT/pe, NEA,
&c. will be correlated. Figure 4 shows, for each study, the distribution of pathway p–value correlations that
each method had with all other methods. A more detailed view is provided in Supplementary Figure File S2.
As above, we use Spearman’s rank correlation as a measure of concordance to account for methodological
differences influencing the dynamic range of p values. NEA analyses tended to give results that disagree with
methods obtained from the other analyses (cf Fig. 4), for reasons we ill discuss further below, while the other
methods are fairly comparable.
While the above comparisons consider correlations for the whole range of p values returned by each
method, we now consider how consistent the selection of “significant” pathways is for the various methods.
The heatmap in Figure 5 depicts the number of times that a pathway was ranked in the top 20% for the 10
studies listed in Table 2. that a pathway was ranked in the top 20%. Results from all subanalyses of each
method are given, including the pORA and pPert values for SPIA and ROT/pe (with and without a cutoff)
that are combined to form the final pComb value for the pathway; the standard pHyper hypergeometric test
and the network edge–based hypergeometric test from PathNet; the results for all six centrality measures
considered by CePa ORA and GSA analyses that are then combined into pComb; and DEGraph results for
the standard Hotelling T 2 test pT2 and the network–smoothed pT2graph for the largest connected component
(lcc) and the full pathway (p’s for all connected componenents combined) for both the signed and unsigned
analyses. The “final” results for each analysis are denoted by bolding. The pathways are sorted by the
average across the bolded analyses, such that (eg) CePa–GSA contributes to that average once as opposed
to seven times. The probabilities for the counts under the null hypothesis are also shown; our expectation is
that we will see, by chance, counts of 0–4 with 95% probability, while counts > 5 should occur only once by
chance amongst the 247 pathways. On the other hand, pathways for which the null hypothesis is indeed false
should exhibit high counts more frequently, corresponding to their detection in multiple studies. Generally,
this pattern appears to qualitatively hold, and the pathways which are deemed significant in > 5 studies
tend to detected consistently by most of the methods (with the exception of NEA). This suggests that the
results are being driven by commonalities across studies, and that those common patterns are detectable by
many of the methods considered.
Distribution of results A more detailed understanding of these patterns emerges from looking at the
concordance between methods for all pathways in all studies, shown in Fig. 6. In the upper triangle of
plots, the joint distributions of − log10 p values are reported; the corresponding correlation coefficients are
shown in the lower triangle. Note that, as above, rank correlation coefficients are reported (and so may differ
from “by eye” estimates). On the diagonal, histograms of − log10 p are plotted in red; the black lines show
the expected distribution of − log10 p corresponding to the uniform distribution of p values expected under
the null. Strikingly, it can be seen from the histograms in Fig. 6 that the p values obtained from NEA are
strongly biased toward highly significant p values; indeed, over half of all NEA pZ values fall ≤ 10−3, whereas
we expect that the proportion would be ∼ 1/1000. This causes an extremely large fraction of pathways to
be deemed statistically significant even after adjusting for multiple hypotheses in NEA, making it difficult
to discriminate truly significant pathways using the current implementation. Such severely skewed p-value
distributions are generally attributable to an incorrect null model.1 The other methods follow the theoretical
p value distributions relatively well, with a slight deviation observed in CePa–GSA.
Discussion
Our review indicates a number of benefits and drawbacks associated with each method, some of which are
inherent to the underlying methodology, and others of which are consequences of the implementations.
1In the case of NEA, we believe there may be a simple remedy for the incorrect null model. Specifically, we note that the
NEA package does not distinguish genes that are assayed and deemed non-significant from genes those that are simply not
assayed. By treating non-assayed genes as insignificant, the proportion of significant genes is significantly reduced, lowering the
probability of significant edges in the resampled graphs.
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Methodological considerations
In Table 1, the design features of each method are listed. A major distinction between the methods is the
need for gene p-value thresholding. Threshold–free analyses are generally considered preferable to those that
require gene–level significance thresholds, since the threshold introduces an arbitrary choice and excludes the
full spectrum of data from the analysis; for this reason, GSEA is preferred to hypergeometric enrichment
tests [7,8] for non-network pathway analyses. Of the network–based methods, SPIA, PathNet, and NEA have
the common drawback of requiring thresholding on gene–level significance; in contrast, CePa and ROT/pe
provide threshold–free options, and the DEGraph and TopologyGSA analyses are threshold–free by design.
However, it should be noted that the cutoff–free ROT/pe analysis differs substantially from the cutoff based
ROT/pe analysis. Specifically, ROT/pe with a cutoff computes both the downstream perturbation analysis
(pPert) and a hypergeometric over-representation analysis (pORA) which are then combined to measure
the impact of differential expression on a pathway, while in the cutoff–free analysis, only the downstream
perturbations pPert are considered. This limitation could be overcome simply by using a GSEA-like analysis
in place of the hypergeometric test, enabling both pORA and pPert to be computed with or without a
threshold.
The second major methodological distinction is in the type of hypothesis being tested by the methods.
“Competitive” null hypotheses compare the pathway of interest to a random pathway while holding the sam-
ple classes (or gene–level associations) fixed, whereas “self-contained” null hypotheses test if the pathway is
more strongly associated with a particular phenotypic attribute than expected by chance given the genes and
topology of the pathway [7]. The two tests represent two different conditional probabilities (“competitive”
being conditioned on the sample labels, allowing the definition of the pathway to vary; the “self–contained”
being conditioned on the pathway definition, but allowing the sample classes to vary), and may thus give
different results. The “self–contained” null is considered superior since it is both better justified biologi-
cally (“competitive” permutations tests will create physiologically unrealistic pathways) and directly answers
the question of whether a particular pathway is associated with the phenotype of interest. Unfortunately,
though, methods testing the “self–contained” null tend also to be limited in the type of data that can be
used: DEGraph, TopologyGSA,and CePa-GSA are limited to two–sample comparisons of continuous data,
making them unsuitable for survival analysis or application to GWAS SNP data. However, while this limi-
tation is inherent to the distributional assumptions made in DEGraph (which uses Hotelling’s T 2 test) and
TopologyGSA (which uses a Gaussian network model), it is only an implementation limitation in CePa-GSA
rather than a methodological constraint. A revision of the CePa package with a more flexible interface would
provide a threshold–free, “self–contained” network analysis tool that could be applied to a broad variety of
studies.
Ease of use
All network methods tested are provided as R or BioConductor packages, making them easily adoptable. In
addition, SPIA, ROT/pe, TopologyGSA,and DEGraph accept R graphNEL [58] objects describing pathways,
making them easy to use with pathway annotation packages such as KEGGgraph [55], GRAPHITE [59],
NCIgraph [60], &c., without additional preprocessing.
A more serious consideration regarding the ease of use is the computation time, shown in Table 3. As
discussed above, most methods are comparably efficient with the exception of NEA and TopologyGSA. We
could identify no methodological factor that contributes to NEA’s lengthy run-time, and believe that it is
likely due to inefficiencies in the R implementation. In contrast, TopologyGSA’s inefficiency is an unavoidable
consequence of the method’s reliance on solving the NP-hard maximal clique problem. The exponential
complexity can easily become intractable for even moderately sized pathways, illustrated in Supplementary
Table S1. At minimum, checks should be built into the TopologyGSA package to conservatively skip pathways
that may fail to be solved in a reasonable amount of time (e.g., by rejecting pathways with more than a
certain number of nodes or edges after moralization and triangulation). However, it is not clear that the
maximal clique problem necessarily needs to be solved. Arguably, simply detecting community structure
within the network (i.e., finding dense subgraphs without requiring that all pairs of nodes are completely
connected as in a clique) is sufficient to define pathway “modules,” which can then be analyzed in the same
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way as the cliques currently are. Detecting community structure/clusters within a graph is readily achieved
by spectral methods [41,42,45,47,48], that solve a relaxation of the problem in O(n3) time. Computational
efficiency of many of these methods could be further improved by parallelized implementations, a feature
that only CePa has to date.
Reliability of results
In absence of “gold–standard” data against which to benchmark these analyses, we attempted to characterize
their reliability based on the concordance of their results in a suite of comparable ovarian cancer studies
(Table 2).
Based on the intuition that studies of similar phenotypes should yield similar results, we examined the
correlation of pathway statistics obtained by each method amongst the 10 studies. In general, we found
greater concordance in the pathway network analysis results than in the simple gene–level analysis (cf.
Figs. 2,3), which was the expected and desirable result from studies of the same phenotype [50]. We also
observed that the network–based analyses generally gave more concordant results than the non-network
GSEA analysis (Fig. 3). The greatest increases in cross–study concordance were obtained with ROT/pe and
CePa (Figs. 2,3). In addition, we expected that meaningful cross–study concordance of pathway results would
be positively influenced by both gene–level concordance and the power of the studies under consideration.
With the exceptions of NEA and the SPIA analyses, the correlation of pathway–level concordance with gene–
level concordance is visible for all methods in Fig. 2, meeting our expectations. The correlation of concordance
with sample size is most clearly manifest only in the CePa-GSA analyses, and, weakly, in DEGraph. We
are thus inclined to believe that the improved cross–study concordance amongst the CePa and DEGraph are
attributable to their detection of common biological signals across the 10 studies.
Based on the conjecture that biological “truths” should be detectable despite slight methodological differ-
ences between the analyses, we also examined the concordance of findings between various methods. Fig. 4
shows the correlations in pathway p values amongst the methods for each study. Most methods yielded
comparable results, with the exception of NEA. Correlations in the pathways consistently identified as being
in the top 20% significant can also be seen amongst SPIA, ROT/pe, PathNet, CePa, and DEGraph in Fig. 5.
By contrast, NEA tends to detect consistently significant pathways that are infrequently found amongst the
top 20% in any study using the other methods.
In addition to investigating the cross–study and cross–method concordance, we also examined the distri-
bution of p values obtained for the methods, shown in Fig. 6. It is expected that most of the 247 pathways
tested are not significantly associated with ovarian cancer, and thus the distribution of p values should be, by
definition, uniformly distributed on [0, 1] with the exception of a handful of significant pathways. However,
as seen in Fig. 6 and discussed above, the network enrichment pZ computed in NEA are exceedingly small a
majority of the time, indicating a likely problem with the null model used in NEA.1
More generally, this observation raises questions about what constitutes an appropriate null model for
network analyses. In the context of the “self–contained” hypothesis tests, the answer is straight–forward: one
permutes the sample labels, leaving the network itself intact. For the “competitive” hypothesis, however, the
answer is far less clear. The difficulties in constructing null models that accurately preserve the statistical
and graph theoretic properties of networks have been considered by ourselves and others [45, 61]. Most
notably, simple randomization of node properties or graph rewiring will produce null models that lack the
assortativity found in biological interaction networks. That is, because of the underlying biology, groups of
genes that are connected in pathway databases will likely exhibit correlated expression (and hence correlated
gene–level significance) in experimental data. By randomizing the data across the network, that property
is destroyed, resulting in network models that are not as structured as those found in nature. Methods
using such null models will yield inflated significance, since the data is being compared against naive random
networks rather than biologically plausible random networks. The test of the “competitive” null hypothesis
thus demands more sophisticated null models than those currently employed. These issues also underscore
the benefit of using a “self–contained” test, which preserves the associations between gene expression and
network structure while randomizing their association with the phenotype of interest.
In general, we find that CePa-GSA exhibits the best cross–study concordance (Fig. 3), does so in a
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way that meets reasonable expectations of being correlated with gene–level concordance and sample sizes
(Fig. 2), and has the benefit of testing the prefered “self–contained” null. The drawbacks of the method,
however, include limitations regarding the input data as discussed above, as well as the fact that CePa returns
several sub–analyses that must be selected or combined by the user, as we did here. CePa-GSA also required
nearly an hour per study when using 1000 permutations, though this may be possible to reduce with CePa’s
parallel implementation. Other methods provide speedier computations and more flexible inputs, albeit at
the expense of improved concordance or other methodological limitations (cf. Table 1)
Conclusions
New network–based methods have garnered increasing interest as tools to analyze complex genomic datasets
at the systems level. Despite the development of a number of promising tools, however, there is little
guidance available to researchers for choosing between the methods. In this review, we sought to compare
all the network analysis methods available in R/BioConductor at the time of this writing [8, 15–26, 36]. In
addition to discussing their methodological and implementation features, we also proposed and applied a
novel means to compare their performance using a suite of curated microarray data-sets [38] and a set of
updated KEGG mappings developed to enable consistent pathway models for each method. The data we
used for the analysis, the prepared KEGG pathways, and the scripts to carry out the computations (including
functions to refresh the curated data and KEGG mappings from their source repositories) have been made
available on the author’s website (http://braun.tx0.org/netRev) to enable other researchers to apply these
comparisons to new methods as they are developed. In addition, we plan to make available updated versions
of our findings as these packages are updated. The results of our tests clearly indicated the benefits and
limitations of each approach. The tests also revealed idiosyncracies that would have been unnoticed except in
comparison; for example, our comparisons revealed a bug in the previous version of the ROT/pe computation,
which led us to suggest a fix that has now been implemented in the current version (reviewed here).
In addition to providing guidance about the features of the methods (Table 1), the efficiency of the
computations (Table 3), and the consistency of the results (Figs. 2–6), our review also suggests a number of
directions for future methodological development.
Most notably, there is a need for benchmark and testing standards against which network analysis methods
should be tested. We used the consistency of the results across a set of comparable studies, but this approach
is plagued by a serious limitation: namely, we have no way to assess whether the “consistent” results are
consistent owing to biological commonalities amongst ovarian cancers or due to a fluke of the microarray
data, since the set is homogenous with respect to the disease type. A more insightful analysis could be
obtained by the development of a database of diverse studies that are all curated to the same standards, just
as was done for the curated ovarian data [38]. While diverse datasets are readily obtained, the work required
to ensure that they are all comparable is non-trivial (and was beyond the scope of this paper); however, such
data would be immensely useful to the research community. Relatedly, agreement on a common pathway
representation format such as BioPAX [6] and developers’ adoption of a consistent API accepting these
pathway files would aid comparison between these methods without requiring that the pathways be prepared
by the user in different ways.
Secondly, we note that the most significant methodological distinctions between the packages involve a
choice between using the preferred “self–contained” null hypothesis versus having the flexibility to apply the
method in contexts other than two–sample differential expression studies. We recommend using methods
that test the self–contained null (both for statistical and biological reasons as discussed above and in [7]), but
at present none of these packages are able to test, for example, a self–contained hypothesis that a pathway
is significantly associated with survival. This compromise could be easily resolved by further development
of CePa–GSA allowing the user indicates to the function the statistical test (or model to be fit) rather than
assuming that a two–sample t-test is desired. In the case of DEGraph, which uses Hotelling’s two-sample
T 2 statistic to compare the graph “smoothed” gene expressions in two phenotypes, such an extension is less
obvious but would be a valuable addition to DEGraph’s functionality.
Relatedly, we note that care must be exercised when constructing null models for the pathways for the
“competitive” tests. An easy check of whether or not the null model is correct is to examine the distribution
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of p values across a large set of pathways; strong deviation from the expected uniform distribution of p
values is indicative of an incorrect null model. However, this rough assessment will only reveal egregious
flaws. In the methods discussed above, and indeed many network biology methods generally, null graphs are
generated by simply resampling node or edge properties. This destroys the correlation structure in the data
(as [8] discussed) as well as the expected assortativity of gene expression in the pathway, yielding excessively
conservative null models. There is thus a need to develop methods that can produce null graphs that are
more biologically plausible.
Finally, we observe that a common drawback to all of these methods is their reliance upon single–gene
statistical tests. As a result, while all of these methods are able to articulate differences in gene expression
that have an impact at the pathway level, they cannot detect differentially regulated pathways when there
are no detectable marginal effects at the gene level. An alternative approach would be to overlay the gene
expression data itself onto the network (instead of using statistics corresponding to the gene’s differential
expression), obtain a summary statistic for the network as a whole, and compare those. This approach
has proved powerful in a non–network context [10, 45], where it was able to detect pathways in which non-
linear patterns of gene expression were associated with phenotype. While network extensions have been
proposed [31], R implementations remain lacking.
Network analysis is rapidly becoming a valuable tool for harnessing existing biological information to yield
mechanistic, systems–level insights from HT data. A number of promising methods have been developed,
and we have found that most yield more consistent results (as measured by cross–study concordance) than
both gene–level analyses and non–network pathway analyses (GSEA [8]). Nevertheless, challenges remain,
and further work in this area has the potential to significantly improve the systems–based analysis of HT
data, facilitating better understanding of the structure and function of the complex networks that coordinate
living processes.
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Gene p-value Expression1 2-sample
Method thresholding data only restriction Directed Signed2 Null type3 Citation
GSEA no no no N/A N/A self-contained [8]
SPIA yes no no yes yes competitive [15,16,36]
ROT/pe optional no no yes yes competitive [16–18]
PathNet yes no no yes no competitive [19]
NEA yes no no no no competitive [20,21]
CePa-ORA yes no no yes no competitive [22,23]
CePa-GSA no as written4 as written4 yes no self-contained [22,23]
DEGraph no yes yes no optional self-contained [24]
TopologyGSA no yes yes no no self-contained [25,26]
Table 1: Properies of the various methods, including whether genes are thresholded on p-values, restrictions on the type of
data and comparisons that can be made, the type of edges used by the model, and the type of null hypothesis tested. Notes:
1 “Expression data” is used here to denote any data that meets the assumptions used in gene expression testing, i.e., that the
data is continuous and normally distributed. Other data meeting these assumptions can also be used, but methods which have
this restriction cannot accept SNP data, etc.
2 “Signed” edges have signs assigned based on the interaction type in the pathway reference graph, distinguishing activating/in-
ducing edges (+1) from repressing/inhibiting edges (-1).
3 “Null type” refers to the type of null hypothesis tested (cf. [7]. “Competitive” null hypotheses compare the pathway of interest
to randomly generated pathways, without permuting sample labels, i.e., testing that the pathway statistic is more significant
than a random pathway given the sample labels. “Self-contained” null hypotheses compare the statistic for the pathway to that
obtained by randomly permuting sample labels, i.e., testing that the pathway is more strongly associated with a particular
phenotypic attribute than expectd by chance given the genes and topology of the pathway. The self-contained null is considered
to be a stronger test [7].
4 CePa-GSA is not inherently restricted to 2-sample tests of differential expression methodologically, however the present imple-
mentation will only carry out the non-thresholded “GSA” type analysis for 2-sample tests of differential expression. As currently
implemented, other types of analyses (e.g., using SNP data or modeling survival) must be carried out in CePa using the “ORA”
analysis, which requires gene p-value thresholding and can only test the competitive null hypothesis3.
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grade
Study Accession No. N(low) N(high)
GSE13876_eset 59 85
GSE14764_eset 24 44
GSE17260_eset 67 43
GSE30161_eset 19 27
GSE32062.GPL6480_eset 131 129
GSE32063_eset 23 17
GSE9891_eset 103 154
PMID17290060_eset 57 57
PMID19318476_eset 17 24
TCGA_eset 75 470
Table 2: Studies and samples sizes of the data used in this investigation. The data are publicly accessible from GEO [62] and
available as part of the curatedOvarianData package.
time (sec), 247 pathways, all 10 studies avg runtime
per studyMethod Package Version user system CPU (usr+sys) wallclock
SPIA SPIA_2.14.0 1229.803 123.825 1353.628 1356.908 2m 15s
ROT/pe, cutoff ROntoTools_1.4.0 948.702 9.497 958.199 959.367 1m 35s
ROT/pe, no cut ROntoTools_1.4.0 1054.795 16.861 1071.656 1076.913 1m 47s
PathNet PathNet_1.2.0 747.983 9.572 757.555 796.516 1m 20s
NEA neaGUI_1.0.0 78099.148 5280.723 83379.871 83389.635 2h 18m 58s
CePa-ORA CePa_0.5 3217.099 21.367 3238.466 3238.537 5m 24s
CePa-GSA CePa_0.5 29127.875 512.618 29640.493 29650.268 49m 25s
DEGraph (s,u) DEGraph_1.14.0 2467.075 43.743 2510.818 2514.990 4m 11s
TopologyGSA topologyGSA_1.4.3 [N/A: job halted after 100hrs] 360000.000
Table 3: Package versions and run times (in seconds) for 247 pathways in all ten studies. Average times (in h/m/s) for a single
study (i.e., 1/10th wallclock) are also noted. Times for computation (“user”) and kernel system calls (“system”) are given; the
total CPU time consumed is the sum of these. The computations were carried out on a lightly–loaded 3.4 GHz quad-core Intel
Core i7 iMac with 16GB RAM running R version 3.0.3 under OS X 10.8.5 (Darwin 12.5.0). Note that the times for DEGraph
include both the signed and unsigned graph analyses. 1000 random permutations were used for the methods that perform
resampling (all except DEGraph).
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Figure 1: Fragment of the KEGG cell-cycle pathway (hsa04110). Classical pathway analyses such as GSEA do not
take the network topology into account, but rather treat the pathway as a simple list of genes. As a result, changes to a gene
such as p53 (red), which has a high degree and a direct influence on a number of other high–degree genes, a large downstream
network, and an outgoing connection to a whole other network (the apoptosis pathway) are treated in the same way as changes
to a gene such as Bub1 (blue), which has far fewer connections. In contrast, topology–based analyses attempt to incorporate
the structure of the network and the relative importance of each gene to the pathway.
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Figure 2: Cross–study concordance for each sub-analysis. For each subcomputation of each method, we show the
correlation between pathway p values for all possible study pairs (45 total). Study pairs are ordered along the x axis according to
their correlation in gene–level p values, shown in the top row. Methods are labeled in alternating colors, with the final/combined
p values denoted in bold. The bottom row of the plot shows the sum of the sample sizes for each pair of studies, with dark
green being high.
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Figure 3: Cross–study correlations. Each plot displays the cross-study correlation of the results for each major analysis
method. Boxplots within each frame indicate, for a given method, the distribution of correlations each study had with the nine
other studies. EG, consider the “GSEA.pES” plot; the blue (leftmost) box indicates the distribution of correlations of GSEA
pathway enrichment score p values (pES) that study ‘GSE13876’ had with each of the other data sets. The red box indicates the
correlations between ‘GSE14764’ GSEA results and those of other nine studies, etc. Cross-study correlations of the gene–level
statistics are also shown. Note that the scale on each of the plots is the same.
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Figure 4: Cross–method correlations. Each plot displays the correlation in p values amongst different methods applied
to each of the data sets. Here, the boxplots within each frame indicate, for a given study, the distribution of correlations the
results from each method had with the others. EG, in the top left frame, the blue (left most) box plot indicates the distribution
of correlation between the pathway enrichment score p values (pES) vs. the pathway p values obtained from the other nine
analyses when applied to the GSE13876 data. Note that the scale on each of the plots is the same.
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Figure 5: Number of studies in which a pathway ranks in the top 20% for each analysis. For each subcomputation
of each method, we show for each pathway the number of times the pathway was amongst the top 20% most significant in each
of the 10 studies. Pathways were only considered significant if they met the 20% cutoff unambiguously; if there were more
than 20% of pathways tied for the top spot, none were considered to be meaningfully in the top 20%. Methods are labeled in
alternating colors, with the final/combined p values denoted in bold. The number of studies (out of 10 possible) in which the
pathway was in the top 20% for that analysis is given by color; black indicates that the method could not give an answer for
that pathway (typically a result of gene thresholding leaving no meaningful edges). The p values in the color scale correspond
to the probability of that specific overlap assuming 10 Bernoulli trials with p = 0.2 success. The 247 pathways are ordered along
the x axis by the mean overlap from the final (bolded) analyses, while the bottom row shows the average across all sub-analyses.
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Figure 6: p-value distributions by method (all pathways, all studies). Depicted are joint and marginal distributions of
− log10(p) values for all pathways in all studies. (Note that higher values are more significant.) In the upper triangle, smoothed
scatter plots depict the joint distribution of − log10(p) for each pair of methods; darker red corresponds to higher density of
points. In the lower triangle, Spearman’s rank correlations ρ between the p values obtained from each pair of methods is given,
with positive correlations shown in increasing blue intensity and negative correlations shown in increasing red intensity (there are
no negative values). Note that because rank correlations provide a measure of concordance that is independent of the dynamic
range of the quantities being correlated and hence less influenced by outliers, the ρ reported in the lower triangle may differ
from a “by eye” estimate of the corrlation based on the plots in the upper triangle. On the diagonal, the marginal distributions
of − log10(p) are shown as red histograms, with the theoretically expected distributions (uniform p under the null) shown as a
black line.
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Supplementary Information
> hsa00190.gnl
A graphNEL graph with directed edges
Number of Nodes = 133
Number of Edges = 132
> (hsa00190.mrl <- moralize(hsa00190.gnl))
A graphNEL graph with undirected edges
Number of Nodes = 133
Number of Edges = 1078
> qpGetCliques(hsa00190.mrl)
1/133 (max 1) 0.00 s (0.00 s/round)
104/133 (max 1) 0.10 s (0.00 s/round)
105/133 (max 1) 0.20 s (0.10 s/round)
106/133 (max 1) 0.41 s (0.20 s/round)
107/133 (max 1) 0.82 s (0.41 s/round)
108/133 (max 1) 1.66 s (0.84 s/round)
109/133 (max 1) 3.32 s (1.66 s/round)
110/133 (max 1) 6.66 s (3.34 s/round)
111/133 (max 1) 13.35 s (6.70 s/round)
112/133 (max 1) 26.78 s (13.42 s/round)
113/133 (max 1) 53.70 s (26.92 s/round)
114/133 (max 1) 107.67 s (53.98 s/round)
115/133 (max 1) 215.86 s (108.19 s/round)
116/133 (max 1) 432.71 s (216.85 s/round)
117/133 (max 1) 866.78 s (434.07 s/round)
118/133 (max 1) 1736.20 s (869.42 s/round)
119/133 (max 1) 3477.42 s (1741.23 s/round)
120/133 (max 1) 6964.69 s (3487.27 s/round)
121/133 (max 1) 13948.89 s (6984.19 s/round)
122/133 (max 1) 27948.81 s (13999.92 s/round)
...
Table S1: R output showing exponential cost of the maximal clique problem for a the oxidative phosphorylation KEGG
pathway. hsa00190 is a modestly sized 133 nodes and 132 edges (below the median across all KEGG graphs). After moralization,
however, it becomes considerably more dense, jumping to 1078 edges. Finding cliques in a graph of this size is a challenging
task. TopologyGSA does this with qpGetCliques(), which is an R interface to the GNU GPL Cliquer library implementing
Östergård’s algorithm [63], the fastest maximal clique algorithm to date. The algorithm uses a branch-and-bound procedure, in
which first small subgraphs of S nodes are searched for maximal cliques. Once found, the size of the subgraph is incremented
and searched again, until either all nodes are in the subgraph S = 133 or when increasing the subgraph would not permit the
maximal clique found to that point. Because maximal clique is an NP-hard problem, the cost increases exponentially with
each increase in subgraph size, as can be seen here with the dense moralized hsa00190 graph. The first column of the timing
output shows the progress of the calculation as the subgraph size is increased. In the second column, the accumulated runtime
is recorded, while the last column gives the amount of time required since the previous search round finished clique was found.
The exponential increase in hardness as is clearly visible. Timing was stopped after approximately 8h, before the algorithm
could complete. Extrapolating from this data, running to completion could take as much as ∼57042500sec, nearly two years.
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Figures S1: supp.xStudyPairs.pdf
Plots of p-value correlations between different studies for each of the 10 methods, along with the gene-wise
p-value correlations. − log10 p values are plotted against each other above the diagonal; below, the correlation
coefficients are given. Note that in NEA (pg 9), a huge number of pathways “saturated” the test, with none
of 1000 permutations yielding statistics comparable to those observed, suggesting possible issues with the
null model.
Figures S2: supp.xMethodPairs.pdf
Plots of p-value correlations between different methods for each of the 10 studies. − log10 p values are plotted
against each other above the diagonal; below, the correlation coefficients are given.
29
